[2] Huang L, Pang D, Yang H, et al. Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial. Nat Commun. 2024 Mar 9;15(1):2153. doi: 10.1038/s41467...
8. Hu X, Curigliano G, Yonemori K, et al. LBA22 Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow...
[5]Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. | Journal of Clinical Oncology https://ascopubs.org...
5.Trastuzumab Deruxtecan in PreviouslyTreated HER2-Positive Breast Cancer. 6.非小细胞肺癌NCCN指南2021V4. 7.Trastuzumab deruxtecan (T-DXd; DS-8201) inpatients with HER2-mutated metastatic non-small cell lung cancer (NSCLC):Interim results of DESTINY-Lung01. 8.Ado-Trastuzumab Emtansine for Patien...
Breast cancer tumors are classified as HER2-positive if they are scored as 3+ by an IHC method defined as uniform membrane staining for HER2 in 10% or more of tumor cells or demonstrate HER2 gene amplification by an ISH method (single probe, average HER2 copy number ≥6.0 signals/cell; du...
批准帕博西尼联合来曲唑用于既往未接受过系统治疗以控制晚期病情的绝经后女性ER+、HER2-晚期或转移性乳腺癌的一线治疗。 联合氟维司群用于接受内分泌治疗后病情进展的HR+、 HER2-晚期或转移性乳腺癌的二线治疗。 批准用于目前老挝也已上市了帕博西尼强仿药——帕西尼(Palbociclib),造福于国内患者,点这里了解离您最...
2.针对HR(+)HER2(-)AN(-)浸润性乳腺癌患者(导管癌、小叶癌、混合癌、化生性癌 ;pT1,pT2, pT3;pN0 ;肿瘤>0.5cm )。 参考文献: [1] Paik,S., et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. New England Journal of Medicine. ...
FDA批准治疗相关生物学标志物列表,对于PIK3CA、AKT1、PTEN激活突变的激素受体阳性HER2阴性肿瘤患者,新增:卡匹色替+氟维司群作为1类首选方案。新增脚注x:对于既往一线或多线内分泌治疗(包括CDK4/6抑制剂)后疾病进展或复发伴PIK3CA、AKT1、PTEN激活突变的成年患者。
Preoperative/adjuvant therapy regimens, HER2-Positive, Useful in certain circumstances: Paclitaxel + trastuzumab + pertuzumab 新增:随后每21天第1天静脉注射曲妥珠单抗6mg/kg+帕妥珠单抗420mg,完成1年治疗 Added: Followed by: Trastuzumab 6 mg/kg IV; Pertuzumab 420 mg IV day 1; Cycled every 21 days ...
12-gene (EndoPredict) treatment implications modified: For patients...The assay is prognostic in endocrine and chemo-endocrine treated patients.The risk score is predictive of chemo-benefit based on a prospective analysis of 3,746 archived, HR-positive, HER2-negative, T1-T3 tumors from chemo-endo...